Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Ligand Pharmaceuticals Incorporated (LGND)

Healthcare Biotechnology

287.50 $

-3.0% vs. previous close

Closing price · As of: 31. Jul 2026

Ligand Pharmaceuticals Incorporated (LGND) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 1,561 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet LGND
Tick rows to compare them in a chart (up to 4)	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	258	534	602	671	1,261	1,495	1,362	1,298	763	787	942	1,561
Current Assets	185	216	163	237	871	1,124	501	465	264	237	332	832
Cash	167	200	141	202	718	72	48	20	45	23	72	175
Cash & Short-Term Investments	167	200	141	202	765	1,070	411	341	212	170	256	734
Receivables	14	12	18	29	56	42	59	92	35	39	42	61
Inventory	0.3	1.6	1.9	4.4	7.1	7.3	26	27	13	24	14	9.1
Property, Plant & Equipment	0.9	0.4	1.8	4.2	5.4	7.2	14	33	27	–	–	–
Goodwill	63	61	277	315	306	95	190	106	106	103	105	102
Intangible Assets	4.6	8.6	26	20	31	231	606	387	353	300	267	422
Total Liabilities	234	230	231	252	700	728	653	476	165	86	111	543
Current Liabilities	23	21	227	239	82	17	100	42	99	17	37	37
Short-Term Debt	0.3	202	213	225	26	1.3	8.5	1.4	77	0.4	1.3	1.1
Accounts Payable	7.7	4.1	9.1	9.6	4.2	2.4	3.8	8.4	5.3	2.4	5.2	3.2
Long-Term Debt	3.1	40	30	19	610	639	442	321	–	–	–	446
Shareholders' Equity	26	304	371	419	561	767	710	821	597	701	830	1,017
Retained Earnings	-659	-402	-431	-401	-229	400	392	449	451	503	499	608
Shares Outstanding	21	21	21	23	24	20	16	17	17	18	18	20

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings